THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION
Authors:
- Chitra SridarCSChitra Sridar
- Ute M. KentUKUte M. Kent
- Paul F. HollenbergPHPaul F. Hollenberg
- 1 June 2005
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 33 (6) , 795-802
Abstract
The polymorphic human cytochrome P450 (P450) 2B6 is primarily responsible for the metabolism of several clinically relevant drugs including bupropion, cyclophosphamide, propofol, and efavirenz. Although a number of single nucleotide polymorphisms have been found in the P450 2B6 gene, the influence of these variants on the metabolism of substrates and on the response to known inactivators of P450 2B6 has not been examined. We have compared the metabolism of different substrates of P450 2B6 (P450 Δ2B6) and the effects of mechanism-based inactivators with that observed with the polymorphic P450 Δ2B6 K262R in a reconstituted monooxygenase system (reconstituted system). Metabolism of bupropion by P450 Δ2B6 K262R resulted in increased production of hydroxybupropion compared with P450 Δ2B6. However, production of formaldehyde from the metabolism of benzphetamine by the P450 Δ2B6 K262R mutant was significantly less than that of the wild-type isozyme. P450 Δ2B6 K262R formed fewer benzphetamine metabolites compared with the wild type. N,N′,N″-Triethylenethiophosphoramide (tTEPA) and bergamottin decreased the ability of both enzymes to hydroxylate bupropion and to O-deethylate 7-hydroxy-4-(trifluoromethyl)coumarin (7-EFC). Incubation with 17-α-ethynylestradiol decreased bupropion hydroxylation and 7-EFC O-deethylation with the wild-type enzyme but had no effect on the mutant. The kinetics for inactivation of the variant by tTEPA and bergamottin were determined using 7-EFC. The KI values for inactivation of the variant were significantly greater than those determined for the wild-type enzyme. These data demonstrate a functional difference between P450 Δ2B6 and the allelic variant P450 Δ2B6 K262R.Keywords
This publication has 26 references indexed in Scilit:
- The Grapefruit Juice Effect Is Not Limited to Cytochrome P450 (P450) 3A4: Evidence for Bergamottin-Dependent Inactivation, Heme Destruction, and Covalent Binding to Protein in P450s 2B6 and 3A5The Journal of Pharmacology and Experimental Therapeutics, 2005
- Metabolism of N,N′,N″-Triethylenethiophosphoramide by CYP2B1 and CYP2B6 Results in the Inactivation of Both Isoforms by Two Distinct MechanismsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimensBiochemical and Biophysical Research Communications, 2004
- SELECTIVE INHIBITION OF CYP2B6-CATALYZED BUPROPION HYDROXYLATION IN HUMAN LIVER MICROSOMES IN VITRODrug Metabolism and Disposition, 2004
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Involvement of human liver cytochrome P4502B6in the metabolism of propofolBritish Journal of Clinical Pharmacology, 2001
- Chemistry, pharmacology and pharmacokinetics of N,N′,N′′ -triethylenethiophosphoramide (ThioTEPA)Cancer Treatment Reviews, 2000
- Molecular Basis for the Differences in Lidocaine Binding and Regioselectivity of Oxidation by Cytochromes P450 2B1 and 2B2Biochemistry, 1998
- Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodeneChemical Research in Toxicology, 1990
- Metabolism of 17 α-ethynylestradiol in humansLife Sciences, 1990